Gut peptides such as GLP-2 decrease turnover in response to feeding, and there has been interest in the possible bone effects of GLP-1 analogues and dipeptidyl peptidase 4 (DPP-4) inhibitors in diabetes treatment. The gene discussed is GCG; the disease is diabetes mellitus.